1.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 74
Sponsor: NCI, Other
Protocol IDs: MA32, U10CA077202, CAN-NCIC-MA.32, CDR0000669788, NCIC-MA.32, NCT01101438
|
|
2.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PCRT 11-002, NCT01488552
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BCC-MEL-11-03, NCT01638676
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: adjuvant metformin for BC, NCT00909506
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: AAAD6525, NCT00930579
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: CDR0000681691, PACT-17, 2010-020979-23, SRSI-PACT-17, EUDRACT-2010-020979-23, EU-21052, NCT01167738
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: AMCmedonc10/003, NCT01210911
|
|
8.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EP-TSC-647, NCT01266486
|
|
9.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: OZM-027, NCT01310231
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 35 to 80
Sponsor: NCI, Other
Protocol IDs: UCI 10-31, NIH, UCI09-13-01, NCT01312467
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MAY10-15-03, NCT01447927
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: METTAX200901, NCT01333852
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 11-009, NCT01340300
|
|
14.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00243, UAZ10-16-01, CDR0000724381, NCT01433913
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0794, NCT01471106
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CROLT/02, 2011-000155-16, NCT01477060
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: G-LUCAS, 200084-610, 2011-001010-34, NCT01523639
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H-28936, NCT01561482
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MET-INCAN-1, NCT01566799
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 19 to 79
Sponsor: Other
Protocol IDs: UMCC 2011.037, NCT01579812
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: KBCSG 013, NCT01589367
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CTRC 10-21, HSC20110273H, NCT01620593
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-1239, NCT01627067
|
|
24.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 134190, NCT01632020
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Fudan BR2012-12, NCT01654185
|
Mobile | Español
